Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure

被引:34
作者
Billebeau, Gilles [1 ,2 ]
Vodovar, Nicolas [2 ,3 ]
Sadoune, Malha [2 ]
Launay, Jean-Marie [2 ,3 ,4 ,5 ]
Beauvais, Florence [1 ,2 ]
Cohen-Solal, Alain [1 ,2 ,3 ,6 ]
机构
[1] Lariboisiere Hosp, Dept Cardiol, Paris, France
[2] INSERM, UMRS 942, F-75010 Paris, France
[3] DHU FIRE, Paris, France
[4] Lariboisiere Hosp, Dept Biochem, Paris, France
[5] Lariboisiere Hosp, Ctr Biol Resources BB 0033 00064, Paris, France
[6] Paris Diderot Univ, Sorbonne Paris Cite, F-75205 Paris, France
关键词
Biomarkers; cardiac rehabilitation; chronic heart failure; peak VO2; BRAIN NATRIURETIC PEPTIDE; VENTRICULAR SYSTOLIC DYSFUNCTION; QUALITY-OF-LIFE; SOLUBLE ST2; B-TYPE; EXERCISE CAPACITY; PROGNOSTIC VALUE; CONTROLLED-TRIAL; TASK-FORCE; VAL-HEFT;
D O I
10.1177/2047487317705488
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiac rehabilitation (CR) improves the symptoms, exercise capacity and quality of life of chronic heart failure (CHF) patients. Its effects on new plasma biomarkers of prognostic importance are unknown. The present study aimed at analysing the effects of a structured CR programme on plasma cardiac biomarkers in a large population of patients with CHF and reduced left ventricular ejection fraction (LVEF). Methods We enrolled 107 consecutive CHF patients with LVEF <= 45% in an ambulatory CR programme. Peak VO2 and plasma levels of Galectin-3, mid-regional proANP (MR-proADM), soluble suppressor of tumorigenicity 2 (sST2) and mid-regional pro-adrenomedullin (MR-proANP) were assessed at inclusion and at the end of CR. Twenty-four unenrolled patients were managed with standard medical care and evaluated over the same period (no-CR group). Results Galectin-3, sST2, MR-proADM and MR-proANP plasma levels decreased after CR, with respective median reductions of 6.3% for Galectin 3 (p < 0.001), 7.4% for sST2 (p = 0.036), 6.4% for MR-proADM (p = 0.001) and 16% for MR-proANP (p < 0.001). MR-proADM was negatively correlated with peak VO2 (p = -0.529, 95% confidence interval [CI] -0.654 to -0.375, p < 0.001), and so were their relative variations along the course of CR (p = -0.357, 95% CI -0.518 to -0.172, p < 0.001). No change occurred in terms of biomarkers in the no-CR group. Conclusions Plasma cardiac biomarkers such as Galectin-3, MR-proADM, sST2 and MR-proANP all decreased after CR in CHF patients, suggesting an overall improvement in the neuro-hormonal profile.
引用
收藏
页码:1127 / 1135
页数:9
相关论文
共 35 条
[1]   Physical training reduces peripheral markers of inflammation in patients with chronic heart failure [J].
Adamopoulos, S ;
Parissis, J ;
Kroupis, C ;
Georgiadis, M ;
Karatzas, D ;
Karavolias, G ;
Koniavitou, K ;
Coats, AJS ;
Kremastinos, DT .
EUROPEAN HEART JOURNAL, 2001, 22 (09) :791-797
[2]   The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure [J].
Ahmad, Tariq ;
Fiuzat, Mona ;
Mark, Daniel B. ;
Neely, Ben ;
Neely, Megan ;
Kraus, William E. ;
Kitzman, Dalane W. ;
Whellan, David J. ;
Donahue, Mark ;
Zannad, Faiez ;
Pina, Ileana L. ;
Adams, Kirkwood ;
O'Connor, Christopher M. ;
Felker, G. Michael .
AMERICAN HEART JOURNAL, 2014, 167 (02) :193-+
[3]   Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT [J].
Anand, Inder S. ;
Rector, Thomas S. ;
Kuskowski, Michael ;
Adourian, Aram ;
Muntendam, Pieter ;
Cohn, Jay N. .
EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (05) :511-518
[4]   Soluble ST2 Serum Concentration and Renal Function in Heart Failure [J].
Bayes-Genis, Antoni ;
Zamora, Elisabet ;
De Antonio, Marta ;
Galan, Amparo ;
Vila, Joan ;
Urrutia, Agustin ;
Diez, Crisanto ;
Coll, Ramon ;
Altimir, Salvador ;
Lupon, Losep .
JOURNAL OF CARDIAC FAILURE, 2013, 19 (11) :768-775
[5]   Randomized, controlled trial of long-term moderate exercise training in chronic heart failure - Effects on functional capacity, quality of life, and clinical outcome [J].
Belardinelli, R ;
Georgiou, D ;
Cianci, G ;
Purcaro, A .
CIRCULATION, 1999, 99 (09) :1173-1182
[6]   Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure [J].
Bristow, MR ;
Saxon, LA ;
Boehmer, J ;
Krueger, S ;
Kass, DA ;
De Marco, T ;
Carson, P ;
DiCarlo, L ;
DeMets, D ;
White, BG ;
DeVries, DW ;
Feldman, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2140-2150
[7]   Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology [J].
Broch, Kaspar ;
Ueland, Thor ;
Nymo, Stale H. ;
Kjekshus, John ;
Hulthe, Johannes ;
Muntendam, Pieter ;
McMurray, John J. ;
Wikstrand, John ;
Cleland, John G. ;
Aukrust, Pal ;
Gullestad, Lars .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (03) :268-277
[8]  
Daniels LB, 2014, FUTUR CARDIOL, V10, P525, DOI [10.2217/fca.14.36, 10.2217/FCA.14.36]
[9]   Galectin-3: a novel mediator of heart failure development and progression [J].
de Boer, Rudolf A. ;
Voors, Adriaan A. ;
Muntendam, Pieter ;
van Gilst, Wiek H. ;
van Veldhuisen, Dirk J. .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (09) :811-817
[10]   Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials [J].
Felker, G. Michael ;
Hasselblad, Vic ;
Hernandez, Adrian F. ;
O'Connor, Christopher M. .
AMERICAN HEART JOURNAL, 2009, 158 (03) :422-430